Table 1 Registration trials in exudative age-related macular degeneration (nAMD), diabetic macular oedema (DMO) and geographic atrophy (GA) from 2006 to 2023.
Condition | Study | Year | Female (%) | White (%) | Hispanic | Black | Asian (%) | Female proportion in Asian subgroup (%) | Other |
|---|---|---|---|---|---|---|---|---|---|
(%) | (%) | ||||||||
AMD | MARINA | 2006 | 64.8 | 96.7 | NA* | NA* | NA* | NA* | 3.3 |
ANCHOR | 2006 | 55.2 | 97.9 | NA* | NA* | NA* | NA* | 2.1 | |
VIEW 1 | 2012 | 58.8 | 96.6 | NA* | 0.24 | 0.1 | 29.4 | 2.14 | |
VIEW 2 | 2012 | 55.5 | 72.3 | NA* | 0.4 | 21.3 | 5.49 | ||
HAWK | 2019 | 56.5 | 81.1 | NA* | 0.36 | 14.7 | NA* | 3.98 | |
HARRIER | 2019 | 57.1 | 92.2 | NA* | 0.26 | 6.1 | NA* | 1.62 | |
TENAYA | 2022 | 60 | 90 | 7.74 | 0.44 | 9 | 28.3 | 0.44 | |
LUCERNE | 2022 | 59 | 83.3 | 12.31 | 1.06 | 10.9 | 0.15 | ||
PULSAR | 2023 | 54.5 | 75.8 | 2.8 | 0.4 | 23.2 | NA* | NA* | |
DMO | RIDE** | 2012 | 41.9 | 81.7 | 26.4 | 10.9 | 3.1 | NA* | 4.54 |
RISE** | 2012 | 44.5 | 77.2 | 18.3 | 13.5 | 5.2 | NA* | 2.91 | |
VIVID | 2014 | 37.9 | 79 | NA* | 0.49 | 19.5 | 6.4 [Japan] | 0.25 | |
VISTA | 2014 | 44.8 | 82.4 | NA* | 10.9 | 2.1 | NA* | 3 | |
KITE | 2022 | 34.7 | 73.6 | NA* | 1.11 | 25.3 | NA* | 20.8 | |
KESTREL | 2022 | 37.3 | 81.6 | NA* | 4.24 | 13.6 | NA* | 13.95 | |
YOSEMITE | 2022 | 40.2 | 78 | 12.12 | 6.27 | 8.9 | 42.3 | 2.44 | |
RHINE | 2022 | 39.1 | 79 | 21.13 | 6.83 | 10.7 | NA* | 0.31 | |
PHOTON | 2023 | 39 | 72 | 18 | 9 | 15 | NA* | 2 | |
GA | OAKS | 2023 | 61.2 | 91.5 | NA* | NA* | NA* | NA* | NA* |
DERBY | 2023 | 60.5 | 94.0 | NA* | NA* | NA* | NA* | NA* | |
GATHER 1 | 2023 | 70.1 | 98.3 | NA* | NA* | NA* | NA* | NA* | |
GATHER 2 | 2023 | 69.4 | 82.3 | NA* | NA* | NA* | NA* | NA* |
